Welcome to Labeled Immunoassays and Clinical Medicine website!

Impact of Tanreqing injection combined with Antibiotics on CRP and PCT in Community Acquired Pneumonia Patients and Its Therapeutic Efficacy

Expand
  • Department of Respiratory and Medicine, the 187th Hospital of PLA, Lanzhou 730000, China

Received date: 2015-04-03

  Revised date: 2015-06-05

  Online published: 2015-09-16

Abstract

Abstract:Objective To investigate the effect of combined Tanreqing injection with antibiotics on C-reactive protein (CRP) and procalcitonin (PCT) in community acquired pneumonia patients. Methods 180 cases of community acquired pneumonia were randomly divided into treatment group and control group. Patients in control group were treated with antibiotics plus conventional symptomatic treatment, and patients in treatment group were treated with Tanreqing injection. The serum levels of PCT and CRP in patients were detected. The comparison of clinical efficacy, bacterial clearance rate, and the changes of PCT and CRP levels and adverse reactions occur. In two groups were analyzed. Results The total effective rate in treatment group (93.3%) was significantly higher than that of the control group (81.1%) (P<0.05). The bacterial clearance rate of the treatment group (94%) was higher than that of control group (82.3%) (P<0.05). The levels of PCT and CRP in both groups after treatment were decreased compared with that of before treatment (P<0.05). The levels of PCT and CRP in the treatment group after treatment were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The Combined Tanreqing injection with antibacterial drugs could have high efficacy and safety, and reduce the level of PCT and CRP in patients with community acquired pneumonia.

Cite this article

ZHENG Chun-xiao,TAN Yong-ming . Impact of Tanreqing injection combined with Antibiotics on CRP and PCT in Community Acquired Pneumonia Patients and Its Therapeutic Efficacy[J]. Labeled Immunoassays and Clinical Medicine, 2015 , 22(6) : 493 . DOI: 10.11748/bjmy.issn.1006-1703.2015.06.005

Options
Outlines

/